Patents Assigned to NUMAB INNOVATION AG
  • Anti-TNF?-antibodies and functional fragments thereof
    Patent number: 10787508
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 29, 2020
    Assignee: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Anti-TNF-alpha-antibodies and functional fragments thereof
    Patent number: 10759852
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 1, 2020
    Assignee: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
    Publication number: 20190194310
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Application
    Filed: March 16, 2017
    Publication date: June 27, 2019
    Applicant: Numab Innovation AG
    Inventors: Tea GUNDE, Sebastian MEYER
  • ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
    Publication number: 20190153089
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Application
    Filed: March 16, 2017
    Publication date: May 23, 2019
    Applicant: Numab Innovation AG
    Inventors: Tea GUNDE, Sebastian MEYER
  • Novel Antibody Frameworks
    Publication number: 20190119359
    Abstract: The present invention relates to novel antibody frameworks with advantageous properties.
    Type: Application
    Filed: October 10, 2018
    Publication date: April 25, 2019
    Applicant: Numab Innovation AG
    Inventors: Sebastian Meyer, David Urech
  • Anti-TNFalpha-Antibodies and Functional Fragments Thereof
    Publication number: 20190092850
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Application
    Filed: March 16, 2017
    Publication date: March 28, 2019
    Applicant: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Antibody frameworks
    Patent number: 10174102
    Abstract: The present invention relates to novel antibody frameworks with advantageous properties. For example, this invention relates to novel chimeric human antibody light chain frameworks, comprising framework regions I to III from V? and framework region IV from V?, with advantageous properties, such as high stability and reduced aggregation propensity.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: January 8, 2019
    Assignee: Numab Innovation AG
    Inventors: Sebastian Meyer, David Urech
  • HETERO-DIMERIC MULTI-SPECIFIC ANTIBODY FORMAT
    Publication number: 20180355024
    Abstract: The invention relates to a novel hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively.
    Type: Application
    Filed: June 15, 2016
    Publication date: December 13, 2018
    Applicant: NUMAB INNOVATION AG
    Inventors: Sebastian MEYER, David URECH